Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FY 2007 Budget In Brief

This article was originally published in The Gray Sheet

Executive Summary

Lab competitive bidding: The Bush administration proposes to introduce market competition into the purchase of laboratory services used to diagnose Medicare beneficiaries in its FY 2007 budget request, released Feb. 6. The measure is expected to save $1.4 bil. by 2011. American Clinical Laboratory Association President Alan Mertz contends that the proposal is premature, as there is no data on which to base expectations of savings, given that the demonstration project for the program, as mandated under the Medicare Modernization Act of 2003, has yet to get off the ground (1"The Gray Sheet" Dec. 5, 2005, p. 13). According to Mertz, two "metropolitan statistical areas" for the demonstration project likely will be announced this month with the demo slated to begin in early 2007. The project is scheduled to last for three years...

You may also be interested in...



Bush’s 2008 Budget: More For FDA Device Center, Less For Medicare Updates

President Bush's fiscal year 2008 budget request, submitted to Congress Feb. 5, includes nearly $7.2 million in new funds and three new staff positions for FDA medical device activities

Bush’s 2008 Budget: More For FDA Device Center, Less For Medicare Updates

President Bush's fiscal year 2008 budget request, submitted to Congress Feb. 5, includes nearly $7.2 million in new funds and three new staff positions for FDA medical device activities

Reimbursement In Brief

Carotid stenting NCD opened: CMS considers expanding coverage for Abbott Vascular's Xact carotid stent system in a national coverage decision opened Aug. 2. Guidant's endovascular business, since acquired by Abbott, requested in a March 31 letter that CMS cover carotid stenting in symptomatic, high surgical risk patients with carotid artery stenosis >50%, and in asymptomatic patients with stenosis >80% that would remove a stipulation in CMS' March 2005 coverage decision that patients with 50%-70% symptomatic stenosis be enrolled in an FDA-approved clinical study (1"The Gray Sheet" March 21, 2005, p. 14). Guidant cites "new and growing evidence" in its request for reconsideration. Consistent with CMS' request that new evidence be made public, Abbott writes in a June 14 letter that results from the Guidant sponsored ARCHeR trial and CAPTURE post-market registry are expected to be published in peer-reviewed journals within the next six months. CMS says this coverage decision will also consider formal accreditation processes for carotid stenting facilities. Initial comments are due Sept. 1, with a proposed decision expected in February...

Related Content

UsernamePublicRestriction

Register

MT023214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel